Rosalind Advisors Inc. Purchases New Position in Replimune Group, Inc. (NASDAQ:REPL)

Rosalind Advisors Inc. acquired a new position in Replimune Group, Inc. (NASDAQ:REPL) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 260,000 shares of the company’s stock, valued at approximately $3,149,000. Replimune Group comprises approximately 1.6% of Rosalind Advisors Inc.’s holdings, making the stock its 18th largest position. Rosalind Advisors Inc. owned 0.38% of Replimune Group at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in REPL. GSA Capital Partners LLP acquired a new position in shares of Replimune Group during the 3rd quarter worth $222,000. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Replimune Group by 25.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 128,208 shares of the company’s stock worth $1,405,000 after purchasing an additional 25,939 shares in the last quarter. Intech Investment Management LLC acquired a new position in Replimune Group during the third quarter worth $252,000. Charles Schwab Investment Management Inc. raised its holdings in Replimune Group by 12.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company’s stock valued at $5,313,000 after buying an additional 52,498 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Replimune Group by 24.9% in the third quarter. The Manufacturers Life Insurance Company now owns 184,208 shares of the company’s stock worth $2,019,000 after buying an additional 36,689 shares during the last quarter. Institutional investors own 92.53% of the company’s stock.

Wall Street Analysts Forecast Growth

REPL has been the topic of a number of analyst reports. Jefferies Financial Group increased their price objective on Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, December 4th. BMO Capital Markets raised their target price on shares of Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. JPMorgan Chase & Co. increased their target price on Replimune Group from $16.00 to $18.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Finally, HC Wainwright increased their price target on shares of Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, February 13th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Replimune Group currently has an average rating of “Buy” and a consensus price target of $19.43.

Replimune Group Trading Down 6.7 %

REPL stock opened at $10.82 on Friday. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14. The business’s 50 day moving average is $12.66 and its 200-day moving average is $12.14. Replimune Group, Inc. has a 1-year low of $4.92 and a 1-year high of $17.00. The firm has a market cap of $833.30 million, a P/E ratio of -3.52 and a beta of 1.30.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Equities analysts anticipate that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.